SCHEMBL837646

SCHEMBL837646

O=C(OCCl)c1cccnc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.64
KMT2A Q03164 4/20 0.64
TDP1 Q9NUW8 3/20 0.64
ALDH1A1 P00352 5/20 0.63
KDM4E B2RXH2 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.62
MEN1 O00255 1/20 0.61
USP2 O75604 1/20 0.61
MAPK1 P28482 1/20 0.57
MAPT P10636 1/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
HPGD P15428 1/20 0.57
AGTR1 P30556 1/20 0.57
CYP2C19 P33261 1/20 0.57
GAA P10253 2/20 0.53
APP P05067 1/20 0.53
HCAR3 P49019 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL312260 0.86 L3MBTL1 (0.68) LMNAKMT2ATDP1ALDH1A1KDM4E
SCHEMBL31023467 0.86 L3MBTL1 (0.68) LMNAKMT2ATDP1ALDH1A1KDM4E
SCHEMBL25009812 0.85 L3MBTL1 (0.76) LMNAKMT2ATDP1ALDH1A1KDM4E
SCHEMBL30556174 0.85 L3MBTL1 (0.76) LMNAKMT2ATDP1ALDH1A1KDM4E
SCHEMBL14741028 0.84 LMNA (0.66) LMNAKMT2ATDP1ALDH1A1KDM4E
SCHEMBL17978281 0.84 KMT2A (0.66) LMNAKMT2ATDP1ALDH1A1KDM4E
SCHEMBL2905998 0.83 ALDH1A1 (0.57) LMNAKMT2ATDP1ALDH1A1KDM4E
SCHEMBL29155474 0.82 LMNA (0.72) LMNAKMT2ATDP1ALDH1A1KDM4E
Ethyl Nicotinate SCHEMBL8164637 0.82 L3MBTL1 (0.71) LMNAKMT2ATDP1ALDH1A1KDM4E
SCHEMBL21243071 0.82 LMNA (0.82) LMNAKMT2ATDP1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359376-B2 Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds SPHAERA PHARMA PTE. LTD (SG) 2016-06-07 US claimed
US-20140121367-A1 SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS PIVOT HOLDING LLC 2014-05-01 US claimed
EP-2693876-A1 SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS Sphaera Pharma Pte. Ltd (SG) 2014-02-12 EP claimed
WO-2012137225-A1 SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS SPHAERA PHARMA PVT. LTD (IN) 2012-10-11 WO claimed
US-12629371-B2 Compositions and methods for inhibiting kinases INHIBIKASE THERAPEUTICS, INC. (US) 2026-05-19 US disclosed
CN-114286811-B Prodrugs of monomethyl fumarate 伊克斯切尔制药有限责任公司 2024-03-08 CN disclosed
WO-2023138612-A1 HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS SILEXON AI TECHNOLOGY CO., LTD. (CN) 2023-07-27 WO disclosed
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 THERAPEUTICS, INC. (US) 2023-03-16 US disclosed
WO-2022253252-A1 HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS SILEXON BIOTECH CO., LTD. (CN) 2022-12-08 WO disclosed
CN-109608436-B Substituted methyl formyl reagents and methods of using same to improve physicochemical and/or pharmacokinetic properties of compounds 斯法尔制药私人有限公司 2022-10-11 CN disclosed
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos C4 THERAPEUTICS, INC. (US) 2022-08-09 US disclosed
CN-114286811-A Prodrugs of monomethyl fumarate 伊克斯切尔制药有限责任公司 2022-04-05 CN disclosed
US-5024998-A Administering in aqueous solution with cyclodextrin derivative UNIVERSITY OF FLORIDA (US) 1991-06-18 US disclosed
US-5017566-A Redox systems for brain-targeted drug delivery UNIVERSITY OF FLORIDA (US) 1991-05-21 US disclosed
US-5002935-A Inclusion Complexing Hydroxypropylcyclodextrin with a Dihydropyridine-substituted Drug UNIVERSITY OF FLORIDA (US) 1991-03-26 US disclosed
US-4983586-A Decreasing precipitation at injection site or in lungs or other organs by combining with hydroxypropyl-beta-cyclodextrin UNIVERSITY OF FLORIDA (US) 1991-01-08 US disclosed
WO-1990004603-A1 NUCLEOSIDE DERIVATIVES NYCOMED AS (NO) 1990-05-03 WO disclosed
EP-0366171-A1 Nucleoside derivatives NYCOMED AS (NO) 1990-05-02 EP disclosed
EP-0335545-A2 Pharmaceutical formulations for parenteral use UNIVERSITY OF FLORIDA (US) 1989-10-04 EP disclosed
EP-0327766-A2 Redox systems for brain-targeted drug delivery UNIVERSITY OF FLORIDA (US) 1989-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos CRBN, IKZF1, IKZF3 LMNA 993/4885KMT2A 415/4885TDP1 1207/4885
US-20140121367-A1 SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS TPMT, BHMT2, PFAS LMNA 3888/4885KMT2A 645/4885TDP1 2511/4885
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS CRBN, IKZF1, IKZF3 LMNA 993/4885KMT2A 415/4885TDP1 1207/4885
US-12629371-B2 Compositions and methods for inhibiting kinases PTK2, HCK, PTK2B LMNA 3839/4885KMT2A 2122/4885TDP1 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.